Impact of VKORC1 haplotypes on long-term graft function in kidney transplantation

Transplantation

Volumn 86, Issue 6, 2008, Pages 779-783

  Quteineh, Lina ^a   Verstuyft, Celine ^b   Durrbach, Antoine ^b   Letierce, Alexia ^c   Ferlicot, Sophie ^b   Charpentier, Bernard ^b   Becquemont, Laurent ^b,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Chronic allograft injury; Genetic polymorphism; Haplotype; Pharmacogenetics; Renal transplantation; VKORC1

Indexed keywords

OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

ADULT; ARTERY INJURY; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAPLOTYPE; HOMOZYGOSITY; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; CONFIDENCE INTERVAL; GENETICS; GENOTYPE; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; CONFIDENCE INTERVALS; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HAPLOTYPES; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTEINURIA; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 56049115619     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818376c7     Document Type: Article

References (30)

1. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 2006; 16: 148.
2. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant 2007; 7: 518.
3. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56: 783.
4. Demetris AJ, Murase N, Ye Q, et al. Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol 1997; 150: 563.
5. Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615.
6. Lacut K, Larramendy-Gozalo C, Le Gal G, et al. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: Results from the EDITH Study. J Thromb Haemost 2007; 5: 2020.
7. Sadler JE. Medicine: K is for koagulation. Nature 2004; 427: 493.
8. Yanagita M, Ishii K, Ozaki H, et al. Mechanism of inhibitory effect of warfarin on mesangial cell proliferation. J Am Soc Nephrol 1999; 10: 2503.
9. Yanagita M, Arai H, Nakano T, et al. Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem 2001; 276: 42364.
10. Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541.
11. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537.
12. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645.
13. Yuan HY, Chen JJ, Lee MT, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14:1745.
14. Quteineh L, Verstuyft C, Descot C, et al. Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. Thromb Haemost 2005; 94: 690.
15. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. NEnglJMed 2005; 352:2285.
16. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773.
17. Larramendy-Gozalo C, Yang JQ, Verstuyft C, et al. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 11730T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol 2006; 98:611.
18. Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135.
19. Schalekamp T, Brassé BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects over-anticoagulation. Clin Pharmacol Ther2006; 80: 13.
20. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140.
21. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-Measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 suppl 1): S1.
23. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137.
24. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003; 349: 2288.
25. Yin JL, Pilmore HL, Yan YQ, et al. Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection. Transplantation 2002; 73: 657.
26. Yin JL, Hambly BD, Bao SS, et al. Expression of growth arrest-specific gene 6 and its receptors in dysfunctional human renal allografts. Transpl Int 2003; 16: 681.
27. Fiebeler A, Park JK, Muller DN, et al. Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am J Kidney Dis 2004; 43: 286.
28. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400.
29. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386:78.
30. Schurgers LJ, Teunissen KJF, Knapen MHJ, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 2005; 25: 1629.